Pfizer Combats Lipitor Diabetes Allegations by Selling the Cholesterol Drug for Cheap

Published on June 3, 2014 by Sandy Liebhard

Text-Size:A A A+


Pfizer is now selling a brand-name version of its chief cholesterol drug for cheap, which may increase the number of people taking it, and thus, the number of Lipitor lawsuit claims filed in the future,  according to

A report published on June 2nd indicates that Pfizer has instituted a new Lipitor Choice program, which sells the medication for less than $30 a month. Patients who get a discount card can receive a supply for that amount if they have no insurance, or are receive coverage through Medicare or Affordable Care Act exchange plans. And those covered by commercial insurance with a co-pay of $130 or less? They will only be charged $4, and Pfizer will cover the rest.

The article states that the company’s new program is its latest attempt to close the Lipitor sales gap that followed its loss of patent protection in November 2011. At its 2006 peak, the cholesterol-lowering medication earned $13 billion for the company in annual sales before off-shoot versions began flooding pharmacies across the U.S.

The generic version of Lipitor, which is marketed as atorvastatin, retails between $8 and $20 per month, according to

Pfizer Pushes Cholesterol Drug Involved in 700 Lipitor Lawsuits

There are negatives to taking this medication, however, which can be counted in the number of Lipitor diabetes lawsuits now filed in the U.S. According to a Case List updated on May 15, at least 703 claims are now pending in a federal litigation established in the U.S. District Court, District of South Carolina. Claimants involved in this proceeding similarly allege that they developed new-onset diabetes after taking the cholesterol-lowering statin, a risk Pfizer failed to adequately warn about in its product marketing. A month earlier, a total of 464 cases have now been centralized in the litigation, which may predict the filing of more cases in the future.

Lipitor diabetes lawsuits in South Carolina federal court similarly allege that its warning label, which was adjusted in February 2012 to include the risk for diabetes, remains insufficient in alerting patients about side effects. After the results of a study released by JAMA: Internal Medicine revealed an increased risk for the disease in post-menopausal women taking Lipitor, the FDA mandated all statin manufacturers to note risk on its labeling.

Considering a Lipitor Lawsuit? Call Us.

Call our Firm today for more information about Lipitor lawsuits, and whether you may be eligible to file a claim alleging new-onset diabetes. Contact us now at .